person · Reporting owner
Lawton Alison Frances
Disclosed activity across 7 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/DNTH · Entity 1813 | Director | May 21, 2026 | May 22, 2026 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director · See Remarks | April 15, 2020 | April 17, 2020 |
| ProQR Therapeutics N.V.PRQR · Entity 5946 | Director | March 18, 2026 | March 18, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
| Verastem, Inc.VSTM · Entity 5242 | Director | June 21, 2019 | June 26, 2019 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | June 10, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date May 21, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $89.63 · Expires 2036-05-21 | Direct | 6,090 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 6,090 · Balance 6,090 F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Kaleido Biosciences, Inc.
Report date April 15, 2020 · Filed April 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2030-04-14 | Direct | 118,500 |
Reported balance
After 2020-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-04-15 · Grant · Acquired 118,500 · Balance 118,500 F1: 25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter.
ProQR Therapeutics N.V.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.89 · Expires 2026-06-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.90 · Expires 2026-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2027-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.78 · Expires 2028-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.91 · Expires 2029-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.20 · Expires 2030-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.01 · Expires 2032-02-29 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: Fully vested. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2033-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2034-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2035-12-31 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Fully vested.
F2: 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F5: 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Verastem, Inc.
Report date June 21, 2019 · Filed June 26, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2029-06-21 | Direct | 25,000 |
Reported balance
After 2019-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-21 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.
X4 Pharmaceuticals, Inc
Report date June 10, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 96,667 |
Reported balance
After 2024-06-10 transaction · row 1
1 source rowRow 1 · 2024-06-10 · Grant · Acquired 45,000 · Balance 96,667 F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CoLucid Pharmaceuticals, Inc.
Report date March 01, 2017 · Filed March 01, 2017
Section 16 reporting ended · disclosed 2017-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.54 · Expires 2026-03-11 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-01 · Disposition to issuer · Disposed 1,420 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.24 · Expires 2026-05-10 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Disposition to issuer · Disposed 8,897 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.20 · Expires 2027-01-03 | Direct | 0 |
Reported balance
After 2017-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-01 · Disposition to issuer · Disposed 658 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
F2: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 22, 2026 20:30 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,090 | $0.00 Strike: $89.63 | $0.00 |
DisclosureSEC source: 0001542650-26-000002 · ownership.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,090 Underlying: Common Stock · 6,090 shares Expires 2036-05-21 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| May 22, 2025 Filed May 22, 2025 20:41 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $18.36 | $0.00 |
DisclosureSEC source: 0000950170-25-076403 · ownership.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:12 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027672 · wk-form4_1718136736.xml · nonDerivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| May 23, 2024 Filed May 28, 2024 23:58 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $21.77 | $0.00 |
DisclosureSEC source: 0000950170-24-065540 · ownership.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The shares of common stock underlying this stock option award will vest in full on the date that is the earlier of (i) the first anniversary of the grant date or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| September 11, 2023 Filed Sep 14, 2023 01:17 UTC | Dianthus Therapeutics, Inc. /DE/ DNTH · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $11.20 | $0.00 |
DisclosureSEC source: 0000899243-23-018867 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-09-10 F1 · derivative.exercise_date: This option represents a right to purchase a total of 6,500 shares of the Issuer's common stock, which will vest in full on the date that is the earlier of (i) the Issuer's 2024 Annual Meeting of Stockholders and (ii) September 11, 2024, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 22, 2023 Filed Jun 30, 2023 20:30 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantStock Option (right to buy) · Derivative | 1,950,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-040328 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,950,000 Underlying: Common Stock · 1,950,000 shares Expires 2033-06-22 F1 · date: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 20:51 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022084 · wk-form4_1686775872.xml · nonDerivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 28, 2022 Filed Jun 30, 2022 22:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0000899243-22-024675 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-27 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 07, 2022 Filed Jun 10, 2022 10:04 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 43,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001209191-22-035691 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 7, 2022, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:17 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018054 · wf-form4_165636101128022.xml · nonDerivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 21:24 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001209191-21-039228 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 8, 2021, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| June 02, 2021 Filed Jun 2, 2021 21:02 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,000 | $9.50 Strike: $9.50 | $57,000.00 |
DisclosureSEC source: 0001628280-21-011543 · wf-form4_162266774296212.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 8.3333% of the shares subject to the option shall vest on July 2, 2021, with the remainder vesting in equal monthly installments of 8.333% of the shares subject to the option until the 12-month anniversary of the date of the grant (or, if earlier, the date of the Issuer's next annual meeting of stockholders following the date of the grant) subject to the Reporting Person continuing to provide services through each such date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 22:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 18,188 | $0.00 Strike: $12.91 | $0.00 |
DisclosureSEC source: 0000899243-21-021848 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,188 Underlying: Common Stock · 18,188 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| December 22, 2020 Filed Dec 24, 2020 00:13 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 36,377 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0000899243-20-035052 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,377 Underlying: Common Stock · 36,377 shares Expires 2030-12-21 F1 · derivative.exercise_date: This option shall vest and become exercisable over three years, with 33% of this option vesting on December 22, 2021, and the remainder vesting in 24 equal monthly installments thereafter. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:33 UTC | Spyre Therapeutics, Inc. AGLE · Entity 2649 | GrantDirector Stock Option (right to buy) · Derivative | 47,200 | $0.00 Strike: $9.09 | $0.00 |
DisclosureSEC source: 0001209191-20-064066 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,200 Underlying: Common Stock · 47,200 shares Expires 2030-12-14 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 36 equal monthly installments beginning on January 15, 2021 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 11:43 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 6,854 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001628280-20-014324 · wf-form4_160198457295532.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,854 Underlying: Common Stock · 6,854 shares Expires 2030-10-04 F1 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on October 5, 2021, with the remainder vesting thereafter in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the grant, subject to the Reporting Person's continued services as a director through each applicable vesting date. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 08:00 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 118,500 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010884 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,500 Underlying: Common Stock · 118,500 shares Expires 2030-04-14 F1 · derivative.exercise_date: 25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:07 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantRestricted Stock Units · Derivative | 46,325 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006859 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,325 Underlying: Common Stock · 46,325 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units shall vest 100% on February 28, 2022. F2 · derivative.expiration_date: The restricted stock units shall vest 100% on February 28, 2022. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 16:05 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.56 | $0.00 |
DisclosureSEC source: 0000899243-19-027503 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-11-14 F1 · derivative.exercise_date: 25% of this option shall vest on November 15, 2020, with the remaining 75% vesting in equal quarterly installments over the next three years. Read SEC document |
| June 21, 2019 Filed Jun 26, 2019 01:40 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001104659-19-037502 · a4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-21 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/21/2019 and ending on 06/21/2020, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 20:12 UTC | Kaleido Biosciences, Inc. KLDO · Entity 129745 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0000899243-19-005960 · doc4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-03-04 F1 · derivative.exercise_date: 25% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| June 11, 2018 Filed Feb 13, 2019 21:53 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0000904454-19-000225 · edgar.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-11 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on 7/11/2018 and ending on 06/11/2019, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date. Read SEC document |
| June 13, 2017 Filed Jun 15, 2017 20:23 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001104659-17-039562 · a4.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: This option will vest in twelve monthly installments through June 13, 2018, with the first monthly installment vesting on July 13, 2017. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:16 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 658 | $10.30 Strike: $36.20 | $6,777.40 |
DisclosureSEC source: 0000911916-17-000074 · edgar.xml · derivative · entry 3 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 658 shares Expires 2027-01-03 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:16 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 8,897 | $40.26 Strike: $6.24 | $358,193.22 |
DisclosureSEC source: 0000911916-17-000074 · edgar.xml · derivative · entry 2 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,897 shares Expires 2026-05-10 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 12:16 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,420 | $39.96 Strike: $6.54 | $56,743.20 |
DisclosureSEC source: 0000911916-17-000074 · edgar.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,420 shares Expires 2026-03-11 F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 16:19 UTC | CoLucid Pharmaceuticals, Inc. CLCD · Entity 12304 | GrantStock Option (Right to Buy) · Derivative | 658 | $30.40 Strike: $36.20 | $20,003.20 |
DisclosureSEC source: 0000911916-17-000020 · edgar.xml · derivative · entry 1 Lawton Alison Frances · CIK 0001542650 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 658 Underlying: Common Stock · 658 shares Expires 2027-01-03 F1 · price: This option was issued to the reporting person pursuant to the CoLucid Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash compensation of $20,000. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.